CompletedNCT05682092Updated Apr 12, 2023

Study of Collagen Efficacy on Skin Anti-aging in 30 to 50-Year-Old Women

An interventional study of WonderLab Collagen Tripeptide Drink and Ordinary Drink in Skin Laxity and Skin Fold, sponsored by Shenzhen Precision Health Food Technology Co. Ltd.,. Completed at 2 sites in China. Open to female participants aged 30 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-12.

Sponsored by Shenzhen Precision Health Food Technology Co. Ltd., · Not applicable, Interventional, and Supportive care

Phase: Not applicable
Study type: Interventional
Enrollment: 70
Allocation: Randomized
Ages: 30 Years to 50 Years
Sex: Female

Study summary

This goal of this clinical trial is to study the efficacy of collagen supplement on skin moisture and elasticity in middle-aged women of 30-50 years old.

Participants will be assigned two products with and without collagen supplement and use for 2 months, twice a day.

Researchers will compare the two groups whether there are siginificant improvement of skin moisture and elasticity for participants via skin measurement and anaysis system.

Read the detailed description

This is a two arms, randomized, double-blind controlled trial. Study product plus collagen supplement and placebo product but without collagen will be randomly assigned to 70 eligible participants who will be enrolled at two study sites in Shanghai. Participants need to use the assigned product one bottle (25ml) each time, twice a day and visit the study site for three times (baseline day, day 30 and day 60) during the 2-month study. For each visit, the primary outcomes (skin hydration and skin elasticity) and secondary outcomes (skin barrier, lines/wrinkles, and facial glow,etc.) will be measured with professional equiment and imaging system and recorded to data management system. At the end of the study, the study data will exported and analyzed to validate the assumption that the collagen could improve skin moisture content and elasticity in middle-aged women of 30-50 years old.

Conditions studied

Skin Laxity
Skin Fold

Browse trials for

Cutis Laxa 147

Keywords

Collagen
skin hydration
skin elasticity
anti-aging

In context

Cutis Laxa

147 studies on the registry are indexed under Cutis Laxa; 35 are open to participants now.

This study's enrollment of 70 is above the median of 30 across 129 interventional studies indexed under Cutis Laxa.

Browse Cutis Laxa studies →

Lead sponsor

Shenzhen Precision Health Food Technology Co. Ltd., is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 30 Years to 50 Years
Sexes eligible: Female
Accepts healthy volunteers: Yes

Inclusion criteria

Chinese females, age between 30-50;
Be in general good health;
Understand the test procedure, read, and sign an appropriate Informed Consent Form indicating their willingness to participate;
Have mild to moderate darker skin tone 3 on Unilever visual scale of 1\~9;
Have mild pigmentation level 2 on Unilever visual scale of 0\~9;
Have visual grading score on crow's feet 3 on Unilever visual scale of 0\~9;
Have visual grading score on peri-oral 3 on Unilever visual scale of 0\~9;
Have visual grading score on nasolabial folds 3 on Unilever visual scale of 0\~9;
Tolerate to well-known anti-aging actives;
Agree to not use any other creams, lotions, moisturizers on the face, other than what is provided for the duration of the study;
Agree to refrain from wearing make-up (such as foundation, eye shadow, lipstick etc.) or any skin care products on the face on the study visits;
Agree to avoid washing the treatment site area for two hours following product application and agree to avoid washing appliances (i.e., sponge, wash cloth, loofah, etc.).

Exclusion criteria

Exclusion Criteria:

Have used any skin lightening /anti-aging benefits products at least one month before this study
Subject having done facial injections and/or aesthetic surgery.
Be involved in any aspect of test administration, i.e., evaluating or overseeing activities related to product.
Have participated in any clinical study involving the test sites within the previous 6 months, or is subject participating in any clinical study concurrently.
Have a history of any type of bottlecer, including but not limited to any type of skin bottlecer (squamous or basal cell carcinoma at the treatment site) or history of malignant melanoma at any body site.
Have a history of skin disease or the presence of a skin condition on the test sites that the Investigator feels would interfere with the study.
Be taking antihistamines (> 3x/week) or anti-inflammatory (> 8x/week) on a regular basis, or has the subject taken systemic or topical steroidal medications within 4 weeks of study enrolment.
Have any of the following conditions or factors that the investigator believes may affect the response of the skin or the interpretation of the test results, including, but not limited to, diabetes, pregnancy, lactation.
Have any cuts/abrasions on the test site at baseline.
Have had a suspicious skin lesion removed by a dermatologist at any time.
The subject is an employee of sponsor or the site conducting the study.

Study design

Phase: Not applicable
Primary purpose: Supportive care
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Double (Participant, Investigator)
Enrollment: 70 participants (actual)

Study arms

Active comparator
WonderLab Collagen Tripeptide Drink
25ml/bottle, containing the following ingredients per 25ml serving: * Collagen 6000 mg * Vitamins C 250 mg * Hyaluronic acid 50 mg * Nicotinamide 0.45 mg
Dietary Supplement: WonderLab Collagen Tripeptide Drink
Placebo comparator
Ordinary Drink
25ml/bottle, containing the following ingredients per 25ml serving: * Peach juice 8 mg * Erythritol 10 mg
Dietary Supplement: Ordinary Drink

Interventions

Dietary supplementWonderLab Collagen Tripeptide Drink
the participant in this arm will use the assigned product 25ml one time, twice a day.
Dietary supplementOrdinary Drink
the participant in this arm will use the assigned product 25ml one time, twice a day.

What researchers measure

Primary outcomes

Skin Elasticity
The changes of skin elasticity by CK Cutometer MPA580
Time frame: baseline day 0, day 30, day 60
Skin Moisture
The changes of skin moisture by Corneometer CM 825
Time frame: baseline day 0, day 30, day 60

Secondary outcomes

Skin Barrier
The changes of skin barrier in terms of TEWL (Trans Epidermal Water Loss) by Aquaflux F200
Time frame: baseline day 0, day 30, day 60
Lines/Wrinkles
The changes of the lines/wrinkles on the face by Miravex Antera 3D imaging system
Time frame: baseline day 0, day 30, day 60
Skin Diagnosis
The skin diagnosis (4 modes and 2 side views) with VISIA CR Facial Imaging System
Time frame: baseline day 0, day 30, day 60

Study locations

2 sites

Ai'er Hospital
Shanghai, Shanghai, China
SPRIM Central Lab
Shanghai, Shanghai, China

References and documents

Publications

Proksch E, Schunck M, Zague V, Segger D, Degwert J, Oesser S. Oral intake of specific bioactive collagen peptides reduces skin wrinkles and increases dermal matrix synthesis. Skin Pharmacol Physiol. 2014;27(3):113-9. doi: 10.1159/000355523. Epub 2013 Dec 24. PubMed 24401291 ↗
Zague V, de Freitas V, da Costa Rosa M, de Castro GA, Jaeger RG, Machado-Santelli GM. Collagen hydrolysate intake increases skin collagen expression and suppresses matrix metalloproteinase 2 activity. J Med Food. 2011 Jun;14(6):618-24. doi: 10.1089/jmf.2010.0085. Epub 2011 Apr 11. PubMed 21480801 ↗
Proksch E, Segger D, Degwert J, Schunck M, Zague V, Oesser S. Oral supplementation of specific collagen peptides has beneficial effects on human skin physiology: a double-blind, placebo-controlled study. Skin Pharmacol Physiol. 2014;27(1):47-55. doi: 10.1159/000351376. Epub 2013 Aug 14. PubMed 23949208 ↗
Nouveau-Richard S, Yang Z, Mac-Mary S, Li L, Bastien P, Tardy I, Bouillon C, Humbert P, de Lacharriere O. Skin ageing: a comparison between Chinese and European populations. A pilot study. J Dermatol Sci. 2005 Dec;40(3):187-93. doi: 10.1016/j.jdermsci.2005.06.006. Epub 2005 Sep 8. PubMed 16154324 ↗
Liang J, Pei X, Zhang Z, Wang N, Wang J, Li Y. The protective effects of long-term oral administration of marine collagen hydrolysate from chum salmon on collagen matrix homeostasis in the chronological aged skin of Sprague-Dawley male rats. J Food Sci. 2010 Oct;75(8):H230-8. doi: 10.1111/j.1750-3841.2010.01782.x. Epub 2010 Sep 24. PubMed 21535500 ↗

Individual participant data

Plan to share: No

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Apr 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT05682092
Lead sponsor: Shenzhen Precision Health Food Technology Co. Ltd.,
Responsible party: Sponsor
First posted: Jan 12, 2023
Start date: Jan 16, 2023
Primary completion: Mar 12, 2023
Completion: Mar 31, 2023
Last update: Apr 12, 2023

Study contacts

Yun Wang, MD

principal investigator · NO. 9 Hospital affiliated to Shanghai Jiao Tong University School of Medicine

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Cutis Laxa→

Other studies from this sponsor

Shenzhen Precision Health Food Technology Co. Ltd.,

Start the discussion